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CD11d/CD18 is the most recently discovered and least understood b2 integrin. Known
CD11d adhesive mechanisms contribute to both extravasation and mesenchymal
migration – two key aspects for localizing peripheral leukocytes to sites of inﬂammation.
Differential expression of CD11d induces differences in monocyte/macrophage
mesenchymal migration including impacts on macrophage sub-set migration. The
participation of CD11d/CD18 in leukocyte localization during atherosclerosis and
following neurotrauma has sparked interest in the development of CD11d-targeted
therapeutic agents. Whereas the adhesive properties of CD11d have undergone
investigation, the signalling pathways induced by ligand binding remain largely
undeﬁned. Underlining each adhesive and signalling function, CD11d is under unique
transcriptional control and expressed on a sub-set of predominately tissue-differentiated
innate leukocytes. The following review is the ﬁrst to capture the nearly three decades of
CD11d research and discusses the emerging role of CD11d in leukocyte migration and
retention during the progression of a staged immune response.
Keywords: beta 2 integrin, CD11d, CD18, leukocyte, migration, extravasation, inﬂammation

INTRODUCTION
The four members of the b2 integrin family, which are surface expressed only on leukocytes, have
critical functions within the innate and adaptive immune systems (1, 2). Various b2 integrin
nomenclatures exist, resulting in each member having multiple designations: CD11a/CD18 (aLb2,
LFA-1, alphaLbeta2), CD11b/CD18 (aMb2, Mac-1, CR3, alphaMbeta2), CD11c/CD18 (aXb2,
p150.95, CR4, alphaXbeta2) and CD11d/CD18 (aDb2, alphaDbeta2) (1, 2). For the following
review, the CD11/CD18 nomenclature will be used exclusively. Acting as adhesion receptors, b2
integrins induce leukocyte adhesion and transmit bidirectional signals (1). Inside-out signalling
describes signalling molecules binding to the cytoplasmic tail and inducing a change in integrin
conformation. Outside-in signalling describes ligand binding to the extracellular I domain and
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transmission of a signal into the cytoplasm (3). The collection of
adhesive and signalling mechanisms form the functionality of b2
integrins in leukocyte trafﬁcking, cytokine release, phagocytosis,
toll like receptor (TLR) signalling, B cell receptor (BCR)
signalling, immunological synapse signalling, and targeted cell
killing (1).
CD11d/CD18 is an understudied member of the b2 integrin
family. First characterized in canines in 1995 (4), CD11d is now
understood to be expressed by a variety of human leukocytes
(5, 6) and to have both adhesion and signalling functions (7, 8).
This review aims to examine known CD11d structure,
expression, functionality, associated pathophysiological states,
and targeted immunomodulatory agents. A focus of CD11d
study has been its role in leukocyte migration, retention, and its
contribution to the harmful accumulation of leukocytes in various
pathophysiological states. Currently, two separate groups are
developing CD11d-targeted agents to modulate the harmful
recruitment of leukocytes following acute neurotrauma (9–12)
and during chronic inﬂammatory disease (13). Less is known
regarding the CD11d protein structure and bidirectional
signalling pathways that have been determined for the other
known b2 integrins. Sequence comparisons, predicted structures,
and predicted functionalities will be presented alongside the
known b2 integrin counterparts to analyse these lesser-known
aspects of CD11d biology.

A

B

FIGURE 1 | Visual representation of b2 integrin structure and conserved
regulatory conformations. (A) Organization of the domains composing the
CD11 and CD18 chains (15, 16). The ligand binding a-I domain is highlighted
by a hatched pattern. The metal ion-dependant adhesion site (MIDAS) and
the socket for isoleucine (SILEN) motifs are located within the a-I domain
(16, 17). The SILEN motif interacts with an invariant isoleucine located in the
a7 helix to maintain the inactive conformation (17). (B) Representation of the
b2 integrin regulatory conformations. The bent-closed inactive conformation
predominates under basal conditions (1). Stimulation can activate the integrin
and induce the extended-closed conformation. Additional stimulation and the
binding of a divalent metal ion to the MIDAS motif, can induce the extendedopen conformation. The bent-open conformation is stabilized by binding a cis
ligand and may provide an alternative activation pathway to the extendedopen conformation (18–20). The extended-open conformation is
characterized by the separation of the cytosolic tails in additional to local
conformational changes within the a-I domain, including shifting of the a7
helix (14–16, 21, 22).

GENERAL b2 INTEGRIN STRUCTURE
Each b2 integrin is a heterodimeric type I transmembrane
protein composed of a variable alpha chain (CD11a-d) and a
common beta chain (CD18). The two chains dimerize noncovalently and each consists of several extracellular domains, a
singular transmembrane domain, and a short cytoplasmic tail
(14) (Figure 1). The conformation and clustering of integrins
heavily regulate their ligand avidity and functionality on the
cellular membrane (21, 22). Multiple factors impact integrin
conformation and clustering including inside-out signalling,
outside-in signalling and thermodynamic equilibriums (21, 23,
24). Four conserved conformations have been observed across
CD11a-c that are labelled: bent-closed, bent-open, extendedclosed, and extended-open (Figure 1) (15, 16, 21, 22, 25, 26).
The bent-closed conformation has a low ligand afﬁnity and is
regarded as inactive. Stimulatory signals can activate the
integrin resulting in the extension of the extracellular domains
into an extended-closed conformation before the transition to
the fully activated extended-open conformation. The fourth
conformation, bent-open, may allow for an alternative
transition pathway to the extended-open conformation (25,
26). The bent-open conformation is stabilized by the binding
of cis ligands – a ligand that is present on the surface of the b2
integrin expressing leukocyte (18–20). The detailed processes
involved in integrin activation are beyond the scope of this
review and we refer the reader to the following articles (16, 21,
27). In leukocytes under basal conditions, b2 integrins
predominately favour an inactive bent-closed conformation
that binds ligands with low afﬁnity (1, 16).
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CD11d GENETICS AND TRANSCRIPTION
FACTORS
The gene encoding CD11d, ITGAD, is located downstream of the
ITGAM (CD11b) and ITGAX (CD11c) genes on chromosome 16
(28–30). All three genes are encoded in the same direction and
clustered separately from ITGAL (CD11a), which is also located
on chromosome 16 (31). Phylogenetic analysis echoes these
observations with CD11a diverging from a common CD11b-d
ancestor (32). The encoded CD11d amino acid sequence shares
the greatest homology with CD11c (70%), followed by CD11b
(59%), while much less homology is shared with CD11a (32%)
(33). Each known CD11 chain has a short and long isoform due
to alternative splicing (28–31). The CD11d short isoform differs
from the long isoform by the absence of a glutamine at residue
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A putative transcription factor also involved in CD11d
regulation is proliferator-activated receptor-g (PPAR-g). Mice
deﬁcient in PPAR-g have splenic red pulp macrophages with
substantially downregulated CD11d mRNA while CD11a and
CD11b mRNA are upregulated (43). Furthermore, sequence
analysis identiﬁes several potential binding sites for PPAR-g
within the CD11d promoter (43). PPAR-g is a member of the
nuclear hormone receptor superfamily and is expressed in a
range of leukocytes including monocytes/macrophages,
neutrophils, lymphocytes, and dendritic cells (44). The
conﬁrmation of PPAR-g binding to the CD11d promoter and
its direct impacts on CD11d regulation have yet to be reported. A
separate study has also postulated a set of CD11d transcription
factors that are involved in myeloid cell differentiation. Oxidized
and acetylated low-density lipoproteins (Ox-LDL and Ac-LDL)
induce the upregulation of CD11d mRNA during HL60 foam cell
formation, but do not impact CD11d mRNA expression in foam
cells (45). Foamy macrophages are known to be involved in
atherosclerosis and drive plaque formation (46). Additionally,
chronic spinal cord injury pathophysiology presents foamy
macrophages within the injury lesion (47). A potential
candidate for this unknown transcription factor involved in
foam cell formation and CD11d expression is PPAR-g (43).
PPAR-g binds to Ox-LDL, is expressed within monocytes/
macrophages, and is involved in foam cell formation (44, 48,
49). Further investigation is warranted to characterize PPAR-g as
a putative CD11d transcription factor and its possible connection
to CD11d upregulation in response to Ox-LDL during foam
cell formation.

500 (30). No study has directly investigated the potential
differences between these two CD11d isoforms. Inclusion and
exclusion of the signal peptide in the residue numbering of the
CD11 chain varies between separate studies. For consistency this
review will position residues along the respective long CD11
isoform and numbering will include the signal peptide sequence.
Mouse models are commonly used to study CD11d because of
the presence of a murine ortholog to each known b2 integrin.
The positioning of all four murine b2 integrin orthologs echoes
the pattern observed in humans. Murine Itgad, Itgax, and Itgam
are encoded in the same direction and clustered separately from
Itgal on chromosome 7 (34–37). Targeted deletion has created
CD11d-/- mice that lack a functional copy of the Itgad gene.
CD11d-/- mice display normal growth, development, fertility,
IgG serum levels, peripheral leukocytes counts, and no increase
in spontaneous infection (38, 39). The weight of murine
CD11d-/- spleens was noted to be heavier than wildtype
spleens at weeks 10-11 but no difference was recorded at weeks
17-18 (38).
The human ITGAD gene is under unique transcriptional
regulation compared to the other b2 integrins (40, 41). Sp1
and Sp3 are shared transcription factors involved in the
regulation of the CD11a-d and CD18 promoters (40). Sp1 is
expressed equally across all leukocytes and induces the basal
expression of CD11d. Meanwhile, Sp3 alters Sp1 basal expression
with cell-type speciﬁc repressor and activator functions (42).
Divergent to CD11a-c, transforming growth factor-b-inducible
early gene-1 (TIEG1) and two isoforms of gut-enriched Kruppellike factor 4 (GKLF/GKLFa) interplay with Sp1 to regulate
CD11d in a cell and stimulant-speciﬁc manner (40, 41).
TIEG1, GKLF/GKLFa, and Sp1 bind to the CD11d promoter
at a common binding site via zinc-ﬁnger DNA binding domains
(40). TIEG1 contains three repression domains and represses
CD11d expression in non-myeloid cells; however, in
differentiated myeloid cells an increase in TIEG1 binding is
coupled with CD11d upregulation (41). The reported role of
TIEG1 in CD11d activation is novel and the exact mechanism of
cell-speciﬁc CD11d activation remains unclear. A leading
hypothesis states that the competition or interaction between
TIEG1 and a set of transcription factors may sum to form the
observed activation of CD11d in differentiated myeloid cells (41).
The complete set of CD11d transcription factors responsible for
these cell-speciﬁc responses is unknown. One known
transcription factor that does compete with TIEG1 to bind the
CD11d promoter and likely impacts CD11d expression is GKLF/
GKLFa. Histone deacetylase 1 and 2 associate with GKLF/GKLFa
bound to the CD11d promoter to repress CD11d expression
across myeloid, non-myeloid, and differentiated myeloid cells
(40). Sp1, TIEG1, and GKLF/GKLFa all contribute to the
bimodal CD11d response to phorbol myristate acetate (PMA)
stimulation observed in myeloid cell lines. Acute 24-hour 10nM
PMA stimulation decreases Sp1 binding, maintains GKLF/
GKLFa binding, and decreases CD11d mRNA expression.
Prolonged 48-hour 100nM PMA stimulation, representing
myeloid differentiation, corresponds with the release of GKLF/
GKLFa, resurgence of Sp1, increase in TIEG1, and CD11d
mRNA upregulation (40, 41).
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CD11d STRUCTURE AND POSTTRANSLATIONAL MODIFICATIONS
Certain conserved motifs heavily regulate the tertiary structure of
the CD11 chain and mediate the known conformational changes.
The open and closed integrin conformations refer to the state of
the a-I domain regulated by a metal ion-dependant adhesion site
(MIDAS) and socket for isoleucine (SILEN) (50) (Figure 1).
These two motifs can impact the position of the a7 helix to either
stabilize the closed or open a-I domain state. Under basal
conditions, the SILEN motif acts to stabilize the closed a-I
domain conformation by interacting with an invariable
isoleucine within the CD11 a7 helix (17) (Figure 2).
Activation can shift the position of the a7 helix and open the
a-I domain MIDAS motif for divalent metal ion binding (14, 16,
17). It is important to note that not all divalent metal ions have
the same effect on the a-I domain conformation. In CD11b, Mg2+
binds the MIDAS motif to stabilize the open state, while Ca2+ binds
the MIDAS motif to stabilize the closed state (58). Separation of the
CD11 and CD18 cytosolic tails is another key conformational
change during integrin activation. The conserved GFFKR or
“hinge” motif maintains the association of the cytosolic tails
during the inactive state (Figure 2). Deletions within the GFFKR
sequence activates the integrin to a high afﬁnity state (52).
Interestingly, the conserved GFFKR +2 tyrosine in CD11b-d is
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FIGURE 2 | Visual representation of a probable CD11d structure including amino acid homolog comparisons of key motifs. (A) Sequence comparison of the CD11d
a-I domain major ligand binding region. The ligand binding CD11d a-I domain is highlighted by a hatched pattern. Residues determined to be important in the ligand
binding pocket of CD11b are underlined and percent homology to CD11d is in brackets. Alignment and CD11b residue analysis performed in previous study (51).
(B) Sequence comparison of the CD11 a7 helix. An invariable isoleucine is highlighted in red and percent homology to CD11d is in brackets. Alignment was
performed in previous study (17). Conformational changes to the a7 helix within CD11d have been shown to alter ligand afﬁnities, thus implying the presence of an
open and closed a-I domain conformation (51). (C) Sequence comparison of complete CD11 cytoplasmic tails. Yellow denotes potential phosphorylation sites, red
denotes conserved residues of interest, and the underlined sequence denotes a potential CK2 site. The GFFKR “hinge” motif is required to maintain the association
of the CD11 and CD18 cytoplasmic tails (52). The constitutive phosphorylation of a serine residue is conserved across CD11a (Ser1165) (53), CD11b (Ser1143) (54),
and CD11c (Ser1158) (55). CD11d has a putative CK2 site at Ser1148-Cys1154 using the consensus sequence (S-X-X-D/E-X-pS-P) (56). The same sequence would
predict Ser1153 to be constitutively phosphorylated as observed in other b2 integrins. The function of the conserved GFFKR +2 tyrosine residue in CD11b-d is largely
undeﬁned. The tyrosine appears to be embedded into the membrane during the inactive conformation, while exposed during the active conformation (57). Long
isoform CD11a (NP_002200.2), CD11b (NP_001139280.1), CD11c (NP_000878.2), and CD11d (NP_001305114.1) amino acid sequences were acquired from the
National Center for Biotechnology Information database (28–31).

activation (Figure 2). Deletion of these serine phosphorylation
sites prevents complete activation and decreases ligand afﬁnity
(53–55). On the CD18 chain, phosphorylation of Thr758 during
inside-out activation is a subsequent requirement for complete
integrin activation. Deletion of the CD18 Thr758 phosphorylation
site impairs adhesion and actin mobilization (61). No study has
yet conﬁrmed a homologous CD11d constitutively phosphorylated
serine; however, three serine residues do exist in the CD11d
cytoplasmic tail, as well as a putative CK2 phosphorylation
site not observed in the other b2 integrins. The constructed
CK2 consensus sequence (56) – S-X-X-D/E-X-pS-P – predicts
CK2 phosphorylation at position S given prior phosphorylation
at position pS. Thus, the putative CD11d CK2 phosphorylation
site at Ser1148-Cys1154 predicts phosphorylation at Ser1148
given constitutive phosphorylation at Ser1153 (Figure 2). The
importance of phosphorylating the alpha chain during outsidein signalling differs between integrin families. Alpha chain
phosphorylation is involved with the respective outside-in
signalling pathways of integrins a3Ab1, a6Ab1, and
a6Ab4 (62). In comparison, the involvement of alpha chain
phosphorylation in b2 integrin outside-in signalling has yet to
be demonstrated (62, 63). The unique presence of a putative

postulated to be hidden within the membrane in the inactive
conformation, while accessible for potential phosphorylation in
the active conformation (57). The role of the conserved GFFKR
+2 tyrosine has yet to be deﬁned but it may play a part in outside-in
signalling. Regarding the presence of these motifs within CD11d, a
crystallized structure has yet to be elucidated thus the conservation
of these structures within CD11d have not been conﬁrmed.
Conservation of key sequences, however, predict the existence of
similar structures within CD11d (Figure 2). Alterations to the
predicted CD11d a7 helix sequence can induce a constitutively
active or inactive afﬁnity state, thus supporting the conservation of
the open and closed a-I domain conformations (51). Ultimately,
structural studies are still required to conﬁrm the presence of the
bent-closed, bent-open, extended-closed, and extended-open
conformations in CD11d/CD18.
Phosphorylation of the CD11 and CD18 cytoplasmic tails are
key to the signalling mechanisms of b2 integrins. The
cytoplasmic tails of CD11a-c are found to be constitutively
phosphorylated whereas the cytoplasmic tail of CD18 is
phosphorylated upon activation (59, 60). Notably in CD11a-c,
a constitutively phosphorylated serine residue on the
cytoplasmic tail is a required step for complete integrin
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the a-I domain of CD11b and a similar Lys261-Lys277 sequence
that is also important for promiscuous ligand binding (Figure 2).
A CD11a/CD18 chimera containing the CD11d Lys261-Lys277
sequence shares the CD11d/CD18 ligand binding speciﬁcity but
with unique binding afﬁnities (51). Additional residues,
therefore, contribute to the complete CD11d binding site.
Future structural studies are required to determine the
structure of this CD11d ligand binding site and determine
key residues.

CD11d CK2 phosphorylation site may translate to the
involvement of alpha chain phosphorylation in CD11d/CD18
outside-in signalling.

CD11d LIGAND SPECIFICITY
The functions of CD11d/CD18 heavily revolve around the
CD11d ligand binding speciﬁcity. b2 integrins are widely
known to bind ligands via the a-I domain (64–66). Initial
studies demonstrated the binding of human CD11d/CD18 to
both human vascular cell adhesion molecule-1 (VCAM-1) and
induced endothelial cell adhesion molecule-3 (ICAM-3) via the
a-I domain (5, 67, 68). The binding afﬁnity for VCAM-1 was
found to be greater than that of ICAM-3 (68). Later work
identiﬁed promiscuous binding to extracellular matrix (ECM)
associated proteins including; ﬁbrinogen, vitronectin,
ﬁbronectin, Cyr61, and plasminogen (51). Recently, CD11d has
been described to bind the protein modiﬁcation 2-(wcarboxyethyl)-pyrrole (CEP), which is a by-product of lipid
peroxidation (13, 69) (Figure 3). As a group, bent-open
b2 integrins have been shown to bind sialylated FcgRIIA,
ICAM-1, and ICAM-3 expressed on the same leukocyte
(18–20). While CD11d has been shown to bind ICAM-3, there
has yet to be direct evidence of CD11d binding ICAM-3 in a
bent-open conformation.
Residues involved in the CD11d ligand binding site were ﬁrst
discovered through homolog studies with CD11b (51). Structural
studies of CD11b determined that Lys261-Arg277 diverges from
CD11a, bestowing promiscuous ligand binding to the CD11b a-I
domain. CD11d shares 60% amino acid sequence homology with

CD11d EXPRESSION
The understanding of human CD11d expression has evolved
over time with expression reported in select human myeloid and
lymphoid cells. Initial investigations noted low expression of
CD11d amongst peripheral blood leukocytes, moderate
expression on myeloid cells, and strong expression on tissuespecialized myeloid cells including splenic red pulp macrophages
and granulocytes, synovial macrophages, and foamy
macrophages (5, 71). Key exceptions were moderate CD11d
expression on peripheral eosinophils and an absence of CD11d
on liver specialized Kupffer cells (5, 67). A later study further
investigated the expression of CD11d on lymphoid cells and
revealed strong expression on B cells and NK cells. Amongst T
cells, gd T cells express CD11d at consistently greater levels than
ab T cells, while Vd1 surface expression on CD11d+ gd T cells is
more prevalent than Vd2 (6) (Table 1).
Detection of CD11d expression does vary across species.
Under basal conditions, CD11d expression is detected at low
levels on murine peripheral blood leukocytes including

FIGURE 3 | Diagram of known CD11d/CD18 ligands. Cellular receptors are shaded green, extracellular matrix proteins are blue, and proteins/protein modiﬁcations
prevalent within the ECM during inﬂammation are red (51, 68). Shared ligand speciﬁcities with CD49d/CD29 is denoted in a red outline (70), while shared ligand
speciﬁcities with CD11b/CD18 is outlined in black (51).
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TABLE 1 | Basal CD11d expression amongst leukocytes of various species.
Organism
Human

Tissue
Periphery

In vitro cultured

Spleen

Mouse

Synovial Joints
Liver
Periphery

Rat

Spleen
Peritoneum
Bone Marrow
Thymus
Liver
Lungs
Periphery

Canine

Lungs
Spleen
Periphery
Spleen
Liver

Cell Type or Sample Source
++

-

CD14 CD16 monocyte
CD14+CD16+ monocyte
B cell
NK cell
ab T cell
gd T cell
Eosinophil
Basophils
Neutrophil
Myeloid derived dendritic cell
Myeloid derived monocyte
6-sulfo LacNAc+ dendritic cell
Splenic red pulp macrophage
Splenic red pulp granulocyte
Synovial macrophage
Kupffer cell
Peripheral leukocyte
Neutrophil
Monocyte
Splenic red pulp macrophage
Peritoneal macrophage
Macrophage
Macrophage
Kupffer cell
Lung homogenate
Peripheral leukocyte
Neutrophil
Monocyte
Lung homogenate
Splenic red pulp macrophage
Peripheral leukocyte
CD8+ T cell
Splenic red pulp macrophage
Kupffer cell

Basal Expression

Reference

+
+
+
++
-/+
+
+
++
+
+
+
++
++++
++++
++
–
-/+
+
+
++++
-/+
++
++
–
-/+
-/+
-/+
-/+
+
++++
-/+
+
++++
–

(7, 72)AB,A
(7, 72)AB,A
(6)A
(6, 73)A,B
(6)A
(6)A
(67)A
(67)A
(7, 67, 73, 74)A,A,A,B
(7)B
(7)B
(73)B
(5)C
(5)C
(71)C
(5)C
(38, 39, 75)A,A,B
(76)A
(76)A
(38, 77)BC,D
(38, 78)A,B
(38)BC
(38)BC
(38)B
(77)D
(79)A
(79)AB
(79)AB
(80)E
(79)AE
(4)A
(4)A
(4)AC
(4)AC

Expression is represented on a scale of – (not detected) to ++++ (highly expressed). A limitation encountered when comparing CD11d expression across studies was the variation in
detection method: ﬂow cytometry (A), immunocytochemistry (B), immunohistochemistry (C), quantitative PCR (D), and western blot (E).

IM-9 (B-cell), and Jurkat (T-cell) (40–42). In myeloid cell lines
(THP-1 and HL60), acute 24-hour 10nM PMA exposure
decreases CD11d mRNA, while prolonged 48-hour 100nM
PMA exposure substantially increases CD11d mRNA (40, 41,
45). Further analysis is still required to determine if the observed
increase in CD11d mRNA results in an increased CD11d/CD18
surface expression. In non-myeloid cells (IM-9 and Jurkat),
northern blot analysis did not detect CD11d mRNA before
or after PMA stimulation (41, 42). Progressing beyond cell
lines, investigations of CD11d upregulation in various
pathophysiological states have further characterized the
regulation of this b2 integrin. CD11d upregulation has been
observed in spinal cord injury (SCI) (74), atherosclerosis (78),
obesity (81), arthritis (71), acute lung injury, and acute respiratory
distress syndrome (ARDS) patients (7). In peripheral blood
eosinophils isolated from the bronchi of allergic patients
challenged with allergen, interleukin 5 was found to upregulate
CD11d surface expression directly (67) (Table 2). An underlying
constraint to all CD11d surface level expression is the coexpression with the CD18 b chain. Without the presence of
CD18, CD11d is retained in the trans-Golgi network and is not
functionally expressed on the cell surface (82).

neutrophils and monocytes (38, 76). One study has described
that murine T cells lack CD11d surface expression, while a
separate study has reported surface CD11d expression on gd T
cells and ab T cells (39, 75). Both studies used ﬂow cytometry. In
canines, CD11d surface expression is extremely low on
peripheral leukocytes, but is present on a small portion of
CD8+ T cells (4). Tissue-specialized myeloid cells mainly
conserve the pattern of expression across observed species.
CD11d protein expression is consistently detected in human,
canine, and mouse splenic red pulp macrophages; however,
CD11d is consistently absent from liver Kupffer cells (4, 5, 38).
IC-21 cells – a peritoneal macrophage cell line from C57BL/6
mice – express CD11d and have been used to model CD11d
ligand binding interactions (51). Finally, investigation within a
rat model demonstrated low CD11d surface expression amongst
peripheral leukocytes and consistent expression amongst splenic
macrophages (79). Rat alveolar macrophages also express low
levels of CD11d protein (80) (Table 1).
Regulation of CD11d expression is cell-type speciﬁc and
inﬂuenced by the temporal duration of leukocyte stimulation.
These regulatory nuances have been modelled across a diverse
set of cell lines: THP-1 (monocytic), HL60 (promyelocytic),
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TABLE 2 | Upregulation of CD11d expression during various disease and injury states.
Disease/Injury

Organism

Atherosclerosis

Human
Mouse
Human
Rats
Mouse
Human
Human
Mouse
Human

Lungs
Lungs
Lungs
Synovial Joints
Lungs
Periphery
Periphery

Human
Mouse

Subcutaneous WAT
Retroperitoneal WAT

Acute Lung Injury or ARDS

Arthritis
Allergen Challenged
LPS-induced endotoxemia
Neurotrauma
Obesity

Tissue

Cell Type or Sample Source

Atherosclerotic lesion

Foamy macrophage
Macrophage
Alveolar Macrophage
Lung homogenate
Lung homogenate
Synovial Macrophage
Bronchoalveolar eosinophil
Neutrophil
Neutrophil
Monocyte
Macrophage
Macrophage

Expression

Reference

++++
++++
+++
+++
+++
+++
++
++
+++
+++
+++
+++

(5)C
(78)A
(7)C
(80)CE
(77)D
(71)C
(67)A
(76)A
(74)A
(74)A
(81)D
(81)D

Expression is represented on a scale of – (not detected) to ++++ (highly expressed). A limitation encountered when comparing CD11d expression across studies was the variation in
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during peritoneal extravasation and the loss of CD11d/CD18
was negated by maintained CD49d/CD29 expression (78). In
comparison, intravenous treatment with a CD11d-targeted
antibody following compression spinal cord injury, but not in
the presence of intraspinal haemorrhage, can reduce the
inﬁltration of peripheral myeloid cells (79, 85, 86). These
results suggest a non-redundant functionality of CD11d/CD18
during the extravasation of peripheral leukocytes into the injured
CNS. Resolving these contradictions may require further
exploration of the differences between various CD11d in vivo
models. First, the contribution of CD11d/CD18 to leukocyte
extravasation could logically be linked to its surface density.
Neutrophil and monocyte surface expression of CD11d is
increased following neurotrauma (74), whereas the
unstimulated monocytes used in the thioglycollate peritonitis
model express low levels of CD11d (78). Additionally, the
differences in physiology may also lead to the described
discrepancy. The process of extravasation into the peritoneum
has been demonstrated to differ uniquely from other tissues
including the lung, skin and cremaster (87).

CD11d IMPACT ON LEUKOCYTE
MIGRATION
Extravasation
Integrins are known to play an important role in leukocyte
extravasation from the periphery into inﬂamed tissues (83).
Leukocyte integrins can interact with endothelium VCAMs
and ICAMs to lock the leukocyte onto the endothelium and
permit diapedesis (83, 84). The loss of functional b2 integrins
impedes leukocyte migration as highlighted in genetic leukocyte
adhesion deﬁciencies (LAD) I and III. In LAD I, CD18
expression is severely diminished, while in LAD III kindlin-3
deﬁciency prevents the activation of b2 integrins in response to
chemoattractants. Both LAD I and III are characterized by
impaired leukocyte localization into inﬂamed tissues and
recurrent infections (15). CD11d has been shown to bind
VCAM-1 and adhere under sheer ﬂow conditions, thus
demonstrating the ability to support leukocyte arrest during
extravasation (68). Integrin CD49d/CD29 (very late antigen 4,
a4b1), also binds VCAM-1 and has as well established role in
leukocyte extravasation (70). Both CD11d and CD49d target
overlapping binding sites on VCAM-1 and could potentially
have redundant functions during leukocyte extravasation (68).
The relative expression of CD11d/CD18 and CD49d/CD29 may
dictate their relative contributions to leukocyte extravasation.
Under basal conditions, CD11d/CD18 would most likely play a
minimal role in VCAM-1 mediated extravasation compared to
CD49d/CD29 as peripheral leukocytes express low levels of
CD11d. Alternatively, these two integrins could be involved in
different stages of extravasation during the progression of an
inﬂammatory response.
Pathology and injury can signiﬁcantly increase CD11d
expression amongst peripheral leukocytes and thus increase
their role in extravasation. The relative contribution of CD11d/
CD18 to leukocyte extravasation during pathology is difﬁcult to
determine because of a shared VCAM-1 binding speciﬁcity with
CD49d/CD29 (Figure 3). A thioglycollate peritonitis model
demonstrated no change in extravasation capacity between
CD11d-/- and wildtype monocytes (78). It was hypothesized
that CD11d/CD18 functions redundantly to CD49d/CD29
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Tissue Migration
The modes of leukocyte tissue migration can mainly be divided
into either amoeboid or mesenchymal migration. Amoeboid
migration is characterized by weak adhesion to the ECM and
the absence of ECM remodelling. In comparison, mesenchymal
migration is characterized by integrin adhesion to the ECM and
remodelling of the ECM by proteolysis (88). All leukocytes can
employ amoeboid migration, while only monocytes/macrophages
are able to partake in either amoeboid or mesenchymal migration
(89). Variable densities of CD11d and CD11b differentially
impact monocyte/macrophage mesenchymal migration (8, 90,
91). A mathematical model has previously described a bell curve
relationship between cell adhesiveness and migration velocity
(92). Integrin adhesion is dependent on integrin density, ligand
afﬁnity, and ligand density. An intermediate value of these three
variables produces the maximum migration velocity (93). Low
density of CD11d expression enhances mesenchymal migration,
whereas high density arrests migration and promotes retention in
inﬂamed tissue (8, 78) (Figure 4).
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FIGURE 4 | Representation of the impact CD11d density has on monocyte/macrophage mesenchymal migration. Low density of CD11d expression supports
migration, while high densities inhibits migration and promotes tissue retention (8).

inﬂammatory pathogen-eliminating cells, whereas M2 macrophages
are anti-inﬂammatory pro-wound healing cells. An immune
response is typically organized by the primary inﬁltration of M1
macrophages before the secondary inﬁltration of M2 macrophages
(94, 95). The cause of M1/M2 macrophage polarization is
contentious and a detailed discussion can be found in the
following review (94). Differential expression of CD11d has been
demonstrated to form different migration patterns between M1 and
M2 macrophages (78, 91). Strong expression of CD11d localizes M1
macrophages to sites of inﬂammation, while moderate CD11d
expression on M2 macrophages is permissive for mesenchymal
migration (91). These observations are supported by M2
macrophages participating in mesenchymal migration across a 3D
matrix, while M1 macrophages are static (89).
Classical CD14+ monocytes are pro-inﬂammatory cells that
primarily localize at the site of inﬂammation, while non-classical
monocytes are pro-wound healing cells that primarily migrate
and patrol (96). Under basal conditions both classical and nonclassical monocytes express low levels of CD11d (7, 72). A
contradiction exists between two studies, however, when
reporting relative expression levels of CD11d between the
monocyte sub-sets. One group reports that non-classical
monocytes have the greater basal expression (72), while the
second group reports greater expression amongst classical
monocytes (7). Both groups analysed CD11d expression using
ﬂow cytometry. Resolving these reported contradictions will
assist in determining if differential CD11d expression
contributes to the staged migration patterns observed between
monocyte sub-sets. In response to strenuous exercise, which does
not alter CD11d expression, non-classical monocytes are
mobilized, while classical monocytes were retained within the
marginal pool (72). In models of neurotrauma (97) and

Retention Following Lipid Peroxidation
The protein modiﬁcation 2-(w-carboxyethyl)-pyrrole (CEP) is a
by-product of lipid peroxidation and a high afﬁnity ligand for
CD11d and CD11b (69). High afﬁnity binding interactions
between CEP adducts and integrins can increase the leukocyte
adhesiveness and arrest monocyte/macrophage mesenchymal
migration. During an inﬂammatory response, an increase in
the abundance of CEP adducts can promote macrophage
accumulation by arresting the migration of monocytes/
macrophages (13, 69). Notably, integrin-CEP binding does not
impact neutrophil migration, presumable because of their
inability to participate in mesenchymal migration (69, 89).
Neutrophils, however, can indirectly increase the prevalence of
CEP adducts within the ECM upon activation and release
of myeloperoxidase. Co-culture of myeloperoxidase and
docosahexaenoate acid – a polyunsaturated fatty acid – increases
the amount of CEP adducts in a ﬁbrin matrix (69). These
discoveries led to the model of a primary wave of neutrophils
initiating lipid peroxidation and producing CEP adducts that “pave
the way” for a secondary wave of macrophages (69). CEP adducts
can arrest monocyte/macrophage migration because high afﬁnity
binding interactions result in substantial increases to leukocyte
adhesiveness. CD11d is postulated to play the primary role in
CEP adduct monocyte/macrophage retention because CD11d
binds CEP adducts with an approximately 10-fold greater afﬁnity
than CD11b (69).

M1/M2 Macrophage Migration
Macrophage heterogeneity heavily impacts the pro-inﬂammatory/antiinﬂammatory balance within an inﬂammatory microenvironment
(94, 95). The spectrum of macrophage heterogeneity can be
described using a M1/M2 paradigm. M1 macrophages are pro-
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in signalling cascade. The distinct sequence variation in the
CD11d cytoplasmic tail may indicate unique signalling
pathways within the CD11d/CD18 outside-in signalling cascade
not observed within the previously described canonical b2
integrin pathways.

myocardial infarction (98), classical monocytes are recruited to
the site of inﬂammation several days before the secondary
recruitment of non-classical monocytes. CD11d expression
levels are increased in unfractionated monocytes following
neurotrauma (74), but no direct link has been made between
CD11d expression and these waves of monocyte sub-set
recruitment. Investigation of the dynamic expression of CD11d
amongst classical/non-classical monocytes and M1/M2
macrophages is warranted in determining if changes in CD11d
levels can impact the staged migration of these cells. Furthering
any knowledge on classical/non-classical monocyte or M1/M2
macrophage migration will be a valuable addition to the current
discussion on the development of M1/M2 polarization during
the progression of various pathophysiological states.

CD11d IN PHAGOCYTOSIS
b2 integrins as a family are known to participate in the
phagocytosis of pathogens and senescent cells (102), but the
role of CD11d in phagocytosis is largely undeﬁned. The initial
identiﬁcation of CD11d expression on splenic red pulp
macrophages linked their function with phagocytosis of spent
and/or infected erythrocytes (5). In contrast to this original
postulate, a study has demonstrated that CD11d/CD18 was not
required for clearance of parasitized red blood cells in a murine
malaria model (38). In CD11d-/- mice, peritoneal macrophages
have no defect in the internalization of latex beads and
phagocytosis of Salmonella Typhimurium (103). Additionally, a
separate study found murine CD11d -/- neutrophils and
macrophages have no defect in the phagocytosis of Escherichia
Coli (76). The current evidence, therefore, does not support
CD11d/CD18 as a required participant in phagocytosis.

IMPACT OF CD11d OUTSIDE-IN
SIGNALLING
b2 integrins have important outside-in signalling pathways
induced by ligand binding. In general, integrins transduce
outside-in signals from an active conformation; however, ligand
binding to the inactive state can induce a conformational change
and thereby transduce an outside-in signal (99). Antibody
binding to the a-I domain in the presence of Mn2+ can also
transmits outside-in signals as demonstrated in CD11b/CD18
(100). Canonical b2 integrin outside-in signalling pathways can
impact cell motility, proliferation, survival, and cytokine
expression. These detailed pathways are beyond the scope of
this review and the reader can refer to the following reviews for
in-depth analysis (2, 101). No outside-in signalling pathway has
yet been elucidated for CD11d/CD18 but impacts of outside-in
signalling have been described. Human monocytes incubated in
wells coated with a variety of anti-CD11d murine monoclonal
antibodies induced cell spreading along with the increased
secretion of IL-8, IL-1b and MCP-1 (7). Human monocytes
also secret IL-8 after binding human ICAM-3, but CD11d/
CD18 is not the only integrin involved in binding ICAM-3 and
transmitting an outside-in signal. Addition of a blocking antiCD11d clone only partially reduces IL-8 secretion. CD11a/CD18
also recognizes ICAM-3 and could function redundantly to
induce IL-8 secretion following ICAM-3 binding (7). A
different signalling impact is detected for CD11d amongst
human NK cells. Interactions between ICAM-3 on neutrophils
and CD11d/CD18 on NK cells have been associated with IFN-g
release in co-cultures stimulated with LPS plus IL-15/IL-18 (73).
Individually, NK cells also release IFN-g following binding to
immobilized ICAM-3 and IL-15/IL-18 stimulation. Application
of a blocking anti-CD18 clone did abrogate NK cell IFN-g release
following ICAM-3 binding but could not differentiate between
CD11d and CD11a signalling contributions (73). These studies
highlight the presence of a CD11d/CD18 outside-in signalling
cascade and the potential difﬁculties in separating the signalling
contributions of individual integrins with shared ligand
speciﬁcities. Future investigation is warranted to characterize
the signalling molecules involved in the CD11d/CD18 outside-
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CD11d IN MACROPHAGE FUSION
Both CD11b/CD18 and CD11d/CD18 have been associated with
the formation of multinucleated giant cells (MNGCs) formed
from the fusion of differentiated macrophages (104). The role an
integrin plays in the process of macrophage fusion is thought to
be proportional to the density of the integrin. CD11d/CD18 is
expressed in a lower density than CD11b/CD18 on macrophages
and likely plays a lesser role in macrophage fusion (104).

CD11d IMPACT ON T CELL
DEVELOPMENT
CD11d expression during thymocyte development impacts the
immunological synapse and T cell proliferation (39). Thymocyte
expression of both CD11b and CD11d has been reported to peak
at days 12-17 in neonatal mice. Following thymic maturation,
individual CD11b-/- and CD11d-/- knockout mice have the most
severe T cell proliferation defects in response to staphylococcal
enterotoxin (SE). The transient CD11b/CD11d co-expression is
hypothesised to be crucial to T cell development as either
knockout develops T cells with reduced CD3, CD28, CD4 and
CD8 expression (39). Interestingly, CD11d-/- mice display
normal T cell proliferation in an experimental autoimmune
encephalomyelitis (EAE) model (105). EAE is designed to
model the autoimmune response to myelin oligodendrocyte
glycoprotein (MOG) observed in multiple sclerosis (106). In
this study susceptible CD11d-/- mice were immunized with the
MOG 35-55 peptide to induce EAE (105). The MOG 35-55
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autoantigen induces a T cell MOG response, but no B cell MOG
response (106). No difference in T cell proliferation was observed
between susceptible CD11d-/- and susceptible wildtype mice
immunized with MOG 35-55 (105). A separate EAE study
noted an increase in CD11a-d/CD18 integrin expression
amongst gd T cells, while no change was observed amongst ab
T cells (75). Notably, CD11d is the only b2 integrin whose
deletion does not improve EAE (105). Further work is warranted
to investigate these conﬂicting T cell proliferation results
and reveal the underlying mechanisms of CD11d/CD18 in
thymocyte development.

with subcutaneous WAT from obese patients compared to lean,
but no trend was observed in omental WAT (81). Like the
retention of M1 macrophages in atherosclerotic lesions, CD11d
upregulation appears to drive M1 macrophage retention in WAT
of obese patients. Targeting CD11d for reduced functional
expression may imped the development of obesity-induced
insulin resistance. CD11d-/- mice have a reduced inﬁltration of
macrophages into adipose tissue, improved glucose tolerance,
and improved insulin sensitivity (91). A small molecule inhibitor
of CD11d, P5 peptide, has been designed to bind to the CD11d
a-I domain and block ligand binding interactions. In prediabetic
mice, P5 peptide application was able to reduce the inﬁltration of
adaptively transferred macrophages into WAT (13).

CD11d IN VARIOUS PATHOLOGIES

Blood-Borne Pathogens
The strong expression of CD11d amongst splenic red pulp
macrophages initiated the investigation into the role of CD11d
in the clearance of blood-borne pathogens. Studies have shown
that CD11d-/- mice have increased survival in response to
malarial Plasmodium berghei infection (38, 77), but a decreased
survival in response to models of polymicrobial sepsis or
S. Typhimurium infection (38, 76, 103). First, splenic red pulp
macrophages are important mediators of parasitic red blood cell
clearance and are maintained within the spleen in a speciﬁc
microanatomic structure. CD11d-/- mouse models of P. berghei
infection demonstrate no defect in splenic microanatomy or
parasitic clearance; however, systemic pro-inﬂammatory
cytokines such as IL-12 were reduced compared to wildtype
(38). The reduction in pro-inﬂammatory cytokines had a large
impact on the development of malaria-associated acute
respiratory distress syndrome (MA-ARDS) within the lungs.
The lungs of CD11d-/- mice had decreased levels of TNF, IL1b, IL-6, IL-12, MCP-1, RANTES, and KC (a murine orthologue
of IL-8). The reduction in pro-inﬂammatory cytokines was
associated with decreased monocyte/macrophage lung
inﬁltration, alveolar-capillary leakage, and mortality (77). In
contrast, CD11d-/- mice have an increased mortality following
cecal ligation and puncture polymicrobial sepsis or LPS-induced
endotoxemia (76). In response to LPS-induced endotoxemia,
CD11d-/- mice display a signiﬁcant decrease in the number of
monocytes/macrophages and an increase in the number of
neutrophils that inﬁltrated into the lungs. No defect in
phagocytosis is observed, but LPS treated CD11d-/- neutrophils
have a signiﬁcant increase in necrosis and pyroptosis compared
to wildtype neutrophils (76). The adaptive transfer of wildtype
neutrophils, but not macrophages, is able to improve the survival
of CD11d-/- mice and is associated with an increase in the
number of lung-inﬁltrating monocytes/macrophages. It is
hypothesized that the increased macrophage number within
the lungs was able to increase the effective efferocytosis of
dead/necrotic neutrophils and confer the survival beneﬁt (76).
The protective role of CD11d in pyroptosis is supported by a
peritoneal S. Typhimurium infection model. Increased
pyrpotosis of peritoneal leukocytes in CD11d-/- mice during S.
Typhimurium infection is coupled with decreased pathogen
killing and increased prevalence of pro-inﬂammatory cytokines
TNFa, MIP-1a, and IL-6 compared to wildtype (103).

Atherosclerosis
Atherosclerosis is a chronic inﬂammatory disease of the
cardiovascular system in which plaques narrow and harden
arteries. Macrophage retention and foam cell formation at
inﬂammatory sites along the arteries contribute to plaque lesion
formation (46, 78, 107). Pro-inﬂammatory M1 macrophages
dominate over anti-inﬂammatory M2 macrophages as the
lesions and disease progress (107). The ﬁrst connections
between CD11d and atherosclerosis arose from observations of
increased CD11d expression on foam cells in atherosclerotic
lesions (5, 45). A recent CD11d knockout study found that
CD11d-/- mice had a decrease in atherosclerotic lesion severity,
altered cytokine production, reduced lesion inﬁltration of M1
macrophages, and a decrease in macrophage CD36 expression
(78). The CD11d-/- mice had a decrease in Fas ligand, MIP-1a, IL6, and IL-12 production, while an increase in IL-13 production
was observed compared to wildtype. The observed change in M1
macrophage lesion accumulation was postulated to be caused by a
change in macrophage mesenchymal migration. An increased
CD11d density may promote macrophage retention instead of
migration within the atherosclerotic lesion (78). Finally, CD36 acts
as an Ox-LDL receptor that contributes to the accumulation of
cytoplasmic Ox-LDL and macrophage foam cell differentiation.
The connection between CD11d, CD36 signalling, and
macrophage foam cell differentiation is currently under
investigation (78).

Obesity Driven Insulin Resistance
Insulin resistance caused by severe obesity is driven by chronic
inﬂammation and macrophage inﬁltration into white adipose
tissue (WAT) (108, 109). The progression to insulin resistance is
characterized by the shift in WAT inﬁltrating M1 macrophages
becoming predominant over M2 macrophages (109). Mouse
models of obesity demonstrate an enormous 300-fold increase
in CD11d mRNA levels within retroperitoneal WAT of obese
animals compared to lean ones. A modest increase was also
observed in CD11b, CD11c, VCAM-1, and ICAM-1 (81). The
increase in b2 integrin expression is connected to macrophage
inﬁltration by a correlated increase in the macrophage
phagocytic marker CD68. Biopsies from female patients
demonstrated a signiﬁcant 6-fold increase in CD11d expression
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Interestingly, the cytokine proﬁles of CD11d-/- and wild type
mice following LPS-induced endotoxemia are not signiﬁcantly
different (76). The perceived conﬂict described regarding the
impact of CD11d on the survival to blood-borne infections may
be resolved by the separate roles CD11d has on monocytes/
macrophages and neutrophils. CD11d is known to impact
monocyte/macrophage mesenchymal migration and monocyte
CD11d outside-in signalling can release pro-inﬂammatory
cytokines (7, 78, 110). In turn, neutrophils do not participate
in mesenchymal migration that can be altered by CD11d density
and little is known regarding neutrophil CD11d outside-in
signalling (89). The protective mechanism of CD11d in
neutrophil necrosis and pyroptosis is not clear, but LPS
treatment does substantially increase neutrophil CD11d
expression while not impacting macrophage CD11d expression
(76). Neutrophils have been described as a “double-edge sword”
during sepsis because the initial wave of neutrophils is key to
combating the infection, but excessive neutrophil pyroptosis
and release of pro-inﬂammatory mediators contributes to a
harmful hyperinﬂammatory state (111). Therefore, the CD11d
neutrophil mechanisms that are important protective factors in
sepsis, but not parasitic infections, may resolve the discrepancy
between CD11d expression and survival to various bloodborne pathogens.

nitration, free radicals, and cell death (115–118). Microarray
analysis elucidated substantial changes in gene expression
following treatment, which peaked at day 3 post injury. AntiCD11d treatment decreased the expression of IL-6 and IL-1b, while
increasing CD4, CD8B, TLR4, and BMP7 (119). These changes to
the inﬂammatory microenvironment are thought to be induced by
the leukocyte population shift within the lesion but could also
indicate alternative activation of leukocytes via the anti-CD11d
treatment. Further investigation is warranted to determine if antiCD11d treatment can induce outside-in signals and alternative
activation of leukocytes. Regardless, the changes to the lesion
microenvironment caused by anti-CD11d treatment spared
myelin and improved the normality of white and grey matter
architecture. Signiﬁcant motor function improvements, reductions
in mechanical allodynia, and reductions in autonomic dysreﬂexia
were all observed following anti-CD11d treatment (9, 10, 120).
A key function of anti-CD11d treatment for acute neurotrauma
is the temporal reduction of peripheral leukocyte inﬁltration into
the site of CNS injury. CD11d can impact leukocyte localization by
contributing to both extravasation and tissue migration. The
inability of anti-CD11d treatment to improve the recovery of
spinal cord injuries with substantial intraspinal haemorrhage
indicates extravasation may be the main CD11d/CD18
mechanism driving peripheral leukocyte inﬁltration (86).
Blocking CD49d/CD29 – an integrin that also contributes to
VCAM-1-mediated extravasation – is also an effective strategy in
treating acute neurotrauma (113). Together CD11d and CD49d
may have a shared role in leukocyte extravasation or contribute to
different stages of extravasation during leukocyte migration into the
injury CNS. These therapeutics support the importance of
extravasation of peripheral leukocytes during acute neurotrauma,
especially in the setting of associated ischemia-reperfusion injury
due to spinal cord compression.
Permitting the second wave of peripheral M2 macrophages is
likely vital to the efﬁcacy of anti-CD11d acute neurotrauma
therapy. Methylprednisolone (MP), a previously standard of care
for neurotrauma, is a general anti-inﬂammatory therapeutic that
spares myelin but does not improve neurological recovery (121,
122). Both MP and anti-CD11d treatments reduce neutrophil and
monocyte/macrophage inﬁltration within 3 days post-injury
compared to untreated. Macrophage and neutrophil inﬁltration,
however, is equal in anti-CD11d and untreated SCI lesions 7 days
post-injury when the pro-wound healing M2 macrophages begin
to predominate. In contrast, MP treatment decreased macrophage
and increases neutrophil inﬁltration compared to untreated at day
7 post-injury (79). Combining both MP and anti-CD11d
treatments abolishes the beneﬁcial neurological improvement
observed in anti-CD11d treatment alone (122). Modulating the
waves of leukocyte inﬁltration, therefore, is more effective than
blocking all waves of leukocyte inﬁltration into the CNS.

Neurotrauma
Neurotrauma is a complex injury that involves multiple injury
stages that progress from an acute inﬂammatory state to a
chronic inﬂammatory state. Following the primary injury, an
inﬂux of peripheral leukocytes into the CNS contributes to
secondary damage through off-target effects (112). The
progression of neurotrauma involves shifts in the prevalence of
M1 vs M2 macrophages at the site of injury. Acute proinﬂammatory M1 macrophages predominate in the lesion
within the acute 2-day period, while M2 macrophages
predominate the subacute 7 to 14-day period. The subacute
period is thought to aid wound healing and improve neurological
recovery. A chronic inﬂammatory stage begins after day 14 and is
characterized by the return to M1 macrophages (97). Unlike
general trauma, neurotrauma induces an increase in CD11d and
CD49d densities amongst neutrophils and monocytes expressing
either of these integrins (74). Therapeutic antibodies have been
designed against both CD11d and CD49d to prevent the acute
extravasation and inﬂux of peripheral leukocytes following
neurotrauma (85, 113).
Administration of an anti-CD11d therapeutic at 2, 24, and 48
hours post-primary injury improves neurological recovery in rat
and mouse models of spinal cord injury (9, 10) and rat models of
traumatic brain injury (11, 12). Treatment is effective if provided
within a 6-8 hour window following the primary injury and if the
treatment continues for 48 hours (79, 114). First, the application of
anti-CD11d reduces the acute inﬁltration of both neutrophils and
monocyte/macrophages into the site of CNS injury (79, 85, 115).
Changes to the leukocyte population within the lesion are coupled
with dramatic changes to the inﬂammatory microenvironment.
Compared to an isotype control, anti-CD11d induces a reduction
in protein oxidation, DNA oxidation, lipid peroxidation, protein
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Lung Injury
In response to lung infection or injury, an overreactive immune
response can result in ARDS and oxygenation failure (123). The
immunopathology of ARDS is exacerbated by the inﬁltration of
peripheral monocytes and neutrophils. The inﬁltration of
peripheral monocytes into the alveolar spaces increases pro-
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inﬂammatory mediators and furthers neutrophil recruitment
(123, 124). Excessive neutrophil recruitment is harmful
because netosis produces neutrophil extracellular traps that
block the alveolar airway (123). Monocyte depletion in a
mouse LPS-induced acute lung injury model can reduce
neutrophil inﬂux, TNF-a production, and the pathological
score. It is hypothesized that the depletion of peripheral
monocytes prevented the interactions between CD4+ T cells
and monocytes that result in the differentiation of Th17 cells
(124). Proliferation of Th17 cells in the lung is associated with an
increase in the production of pro-inﬂammatory mediators that
contribute to ARDS pathology, notably IL-17. Potential ARDS
therapies, therefore, could target the migration of peripheral
monocytes into the inﬂamed lungs (124).
Strong CD11d expression is observed in the lung tissue of
deceased ARDS patients (7). A rat IgG-immune complex-induced
lung injury model demonstrated CD11d upregulation within the
lungs (80). Application of a rabbit polyclonal anti-CD11d,
therefore, was hypothesized to decrease the severity of acute
lung injury within the rat IgG-immune complex-induced model.
Indeed, decreases in lung injury, neutrophil inﬂux, TNF-a levels,
and NO−2 =NO−3 levels were observed following rabbit polyclonal
anti-CD11d application. The production of NO−2 =NO−3 in rat
alveolar macrophages in vitro was also decreased by the
application of the rabbit polyclonal anti-CD11d (80). Recalling
the previous analysis of CD11d in MA-ARDS, decreased
monocyte inﬁltration was observed in CD11d-/- mice compared
to wildtype. Furthermore, CD11d-/- mice demonstrated reduced
levels of pro-inﬂammatory cytokines including TNF and MCP-1
(77). In addition to lung infection or injury, ARDS can also be
induced by systemic inﬂammation caused by trauma (123).
Neurotrauma has been shown to induce systemic inﬂammatory
response syndrome (SIRS), in which peripheral leukocytes
inﬁltrate organs and cause damage (125–127). A retrospective
study of 193 acute traumatic SCI patients found 47% had at least 2
SIRS criteria (128). Neurotrauma induced SIRS can induce lifethreating lung damage and ARDS due to the inﬁltration of
peripheral leukocytes (125). A single dose of anti-CD11d
treatment at 2 hours following neurotrauma models can
decrease neutrophil inﬁltration, macrophage accumulation, lipid
peroxidation, protein nitration, and cell death within the lungs
(126, 127). Anti-CD11d may abrogate the extravasation of
peripheral monocytes and neutrophils into the alveolar spaces.
Additionally, anti-CD11d may induce outside-in signalling that
modulates the production of pro-inﬂammatory mediators by
alveolar macrophages. Both CD11d/CD18 leukocyte localization
and outside-signalling mechanisms, therefore, probably contribute
to the immunopathology of acute lung injury and ARDS.

within in vivo mouse and rat models (9–11, 114, 115, 120). A
peptide inhibitor, P5 peptide, has also been developed to block
CD11d-ligand interactions during macrophage mesenchymal
migration (13). In vitro P5 peptide experiments demonstrated
that the therapeutic was able to alter wildtype macrophage
migration in a 3D matrix, while not impacting diapedesis. The
therapeutic was then able to successfully transition into an in vivo
model of prediabetic mice to prevent the accumulation of
macrophages in WAT (13). P5 peptide therapy, therefore, is
positioned to treat chronic inﬂammatory diseases where CD11d
contributes to the harmful accumulation of macrophages.
Understanding off-target effects in addition to CD11d ligand
binding are important in ensuring therapeutic safety. Both
therapeutic agents target the ligand-binding a-I domain of
CD11d, which could initiate integrin activation and/or outsidein signalling. Preliminary experiments report that P5 peptide may
lock CD11d/CD18 into an intermediate state and prevent integrin
activation (13). Further studies are still required to conﬁrm this
impact of P5 peptide on the CD11d/CD18 structure. Similar
structural experiments between anti-CD11d therapy and
CD11d/CD18 have yet to be performed. Previously, therapeutic
attempts that targeted b2 integrins were not successful in
translating into the clinic due to pervasive off-targeted effects.
Efalizumab is an anti-CD11a therapeutic designed for long-term
administration to treat chronic plaque psoriasis (129). CD11a is
consistently expressed on all leukocytes and the systemic blockage
of CD11a/CD18 activity led to severe side effects. Efalizumab was
eventually discontinued due to the reactivation of JC virus and the
development of fatal progressive multifocal leukoencephalopathy
(130, 131). Currently, anti-CD11d therapeutics are mainly being
developed for short-term use in acute inﬂammatory settings. A
deeper understanding of CD11d expression and the afﬁnity to
each CD11d/CD18 conformation will assist in elucidating the
range of potential side effects from these focused CD11dtargeted therapeutics.

CONCLUSION
Integrins are an essential part of the immune system and the
discovery of CD11d/CD18 expanded the breadth of the b2
integrin family. To date, however, CD11d/CD18 remains the
least understood b2 integrin with major gaps in the knowledge
of its structure and signalling pathways. Exciting discoveries have
been made on the impact of CD11d/CD18 on leukocyte migration,
retention, and coordination of a staged immune response.
Emerging evidence demonstrates that differences in CD11d
density may contribute to the differences in M1/M2 migration
patterns, while CD11d speciﬁcity to CEP adducts from lipid
peroxidation may contribute to the staging of neutrophil and
monocyte/macrophage waves. CD11d-targeted therapeutic agents
have been designed to modulate the localization of leukocytes
during the progression of diseases or injuries. The dual impacts of
CD11d/CD18 on cytokine release and localization of leukocytes,
however, confound the therapeutic mechanism(s) of action that
alter the inﬂammatory microenvironment. Ample opportunities
exist to further the basic knowledge of CD11d/CD18 biology,

CD11d-TARGETED THERAPIES
Currently, two therapeutic agents have been developed to target
CD11d and modulate leukocyte migration during disease/injury
development. A therapeutic anti-CD11d monoclonal antibody has
been developed to block the inﬁltration of peripheral leukocytes
into the CNS during acute neurotrauma and extensively studied
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which will propel the exciting developments of CD11d-targeted
biological agents.
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